When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Seltorexant - Wikipedia

   en.wikipedia.org/wiki/Seltorexant

   Seltorexant, also known by its developmental code names MIN-202 and JNJ-42847922, is an orexin antagonist medication which is under development for the treatment of depression and insomnia. [3] [2] It is a selective antagonist of the orexin OX 2 receptor (2-SORA). [2] [4] [1] The medication is taken by mouth. [1]

3. Lemborexant - Wikipedia

   en.wikipedia.org/wiki/Lemborexant

   Lemborexant is used in the treatment of insomnia in adults. [3]A major systematic review and network meta-analysis of medications for the treatment of insomnia published in 2022 found that lemborexant had an effect size (standardized mean difference (SMD)) against placebo for treatment of insomnia at 4 weeks of 0.36 (95% CI Tooltip confidence interval 0.08 to 0.63) and at 3 months of 0.41 (95% ...

4. List of investigational sleep drugs - Wikipedia

   en.wikipedia.org/wiki/List_of_investigational...

   This is a list of investigational sleep drugs, or drugs for the treatment of sleep disorders that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

5. Ramelteon - Wikipedia

   en.wikipedia.org/wiki/Ramelteon

   Ramelteon, sold under the brand name Rozerem among others, is a melatonin agonist medication which is used in the treatment of insomnia. [3] [5] It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset. [3]

6. Drugs You Don't Need For Disorders You Don't Have - The ...

   highline.huffingtonpost.com/articles/en/sleep...

   Under pressure from lobbyists and Capitol Hill, the FDA in 1997 produced new guidelines declaring that companies’ ads just had to devote roughly equal time to the risks and benefits of a drug. One year later, spending on television drug ads had more than doubled, from $310 million to $664 million.

7. Tasimelteon - Wikipedia

   en.wikipedia.org/wiki/Tasimelteon

   A phase III insomnia trial was conducted in 2006. [12] A second phase III trial on insomnia, this time concerning primary insomnia, was completed in June 2008. [13] In 2010, the FDA granted orphan drug status to tasimelteon, then regarded as an investigational medication, for use in totally blind adults with N24HSWD. [14] (Through mechanisms ...